Deucravacitinib Patent Expiration
Deucravacitinib is Used for treating moderate-to-severe plaque psoriasis in adults who may benefit from systemic therapy or phototherapy. It was first introduced by Bristol Myers Squibb Co
Deucravacitinib Patents
Given below is the list of patents protecting Deucravacitinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sotyktu | US10000480 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | Nov 07, 2033 | Bristol |
| Sotyktu | US11021475 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | Nov 07, 2033 | Bristol |
| Sotyktu | USRE47929 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | Nov 07, 2033 | Bristol |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Deucravacitinib's patents.
Latest Legal Activities on Deucravacitinib's Patents
Given below is the list recent legal activities going on the following patents of Deucravacitinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Dec, 2021 | US10000480 |
| Sequence Moved to Public Database | 01 Jun, 2021 | US11021475 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Jun, 2021 | US11021475 |
| Recordation of Patent Grant Mailed Critical | 01 Jun, 2021 | US11021475 |
| Issue Notification Mailed Critical | 12 May, 2021 | US11021475 |
| Dispatch to FDC | 04 May, 2021 | US11021475 |
| Letter Accepting Correction of Inventorship Under Rule 1.48 | 03 May, 2021 | US11021475 |
| Filing Receipt - Updated | 03 May, 2021 | US11021475 |
| Application Is Considered Ready for Issue Critical | 03 May, 2021 | US11021475 |
| Issue Fee Payment Received Critical | 29 Apr, 2021 | US11021475 |
Deucravacitinib's Family Patents
